General public
You are here
The PETAL Network
The Clinical Trials Network for the Prevention and Early Treatment of Acute Lung Injury (PETAL Network) is a network of 12 Clinical Centers (CC) and 1 Clinical Coordinating Center (CCC) funded by the National Heart, Lung, and Blood Institute (NHLBI) to develop and conduct randomized controlled clinical trials to prevent or treat, and/or improve the outcome of patients who have, or who are at risk for, Acute Lung Injury (ALI) or Acute Respiratory Distress Syndrome (ARDS).
Participating in Research
The 411 on being a research subject
Lungs 101
Get the basics on the respiratory system
Critical Illness
Terminology and other info explained
Primary studies
Ancillary studies
News
It is with the heaviest of hearts and deepest sorrow that the PETAL Network notes the passing of CCC Biostatistician Douglas Hayden on June 2, 2023.
His obituary can be found on Boston Cremation.
From the NHLBI announcement: No differences found between liberal or restrictive fluid treatment strategies for septic-induced hypotension:
NHLBI PETAL Network ends Phase 3 sepsis trial early
PETAL Network study found no significant difference in 90-day mortality rates, nor safety concerns, after providing patients with one of two common treatment strategies
Major US Trial Closes Showing No Benefit for Hydroxychloroquine in COVID-19
June 20, 2020
On behalf of the PETAL Network, we are excited to share that two of the primary manuscripts have been published in the New England Journal of Medicine.